CML, characterized by the BCR/ABL gene rerrangement has been more extensively studied than any other malignancy. Over the last decade, significant progress has been made in our understanding of BCR-ABL-induced alterations in intracellular signaling. Unfortunately, we still only poorly understand the correlation between the clinical symptoms of chronic phase CML and the BCR-ABL oncoprotein. This is in part due to lack of a good in vivo animal model of chronic phase CML. In vivo and in vitro studies from the Clarkson group, recently reviewed in this journal (Leukemia 1997; 11: 1404-1428), have significantly enhanced our understanding of the pathophysiology of CML. However, further characterization of the effect of the BCR-ABL oncoprotein on signal molecules involved with cell differentiation, cell proliferation, cell survival and cell adhesion in primary Ph ؉ CML progenitors or in vivo models of CML will be needed to provide a full understanding of the pathophysiology of chronic phase CML.
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Chronic myelogenous leukemia (CML) is a malignancy of the human hematopoietic stem cell 1 characterized by a reciprocal translocation between chromosomes 9 and 22, termed the Philadelphia chromosome (Ph) 2 resulting in the formation of a hybrid BCR-ABL gene on chromosome 22. 3 BCR-ABL cDNA introduced in hematopoietic cell lines causes growth factor independent growth in vitro and tumorigenicity in vivo. 4 Mice transplanted with stem cells transduced with BCR-ABL cDNA develop a CML-like syndrome. 5 This supports the notion that the BCR-ABL oncoprotein is necessary and sufficient for the development of CML.
In its chronic phase, CML is characterized by an abnormal, unregulated expansion of Ph + myeloid, erythroid and megakaryocytic progenitors in the marrow. The number of myeloid, but not erythroid, precursors and cells is also increased, with a special predilection for the basophil lineage. Ph + stem cells, progenitors and precursors circulate prematurely in the peripheral blood and 'home' to extramedullary locations. Finally, Ph + progenitors have a significantly increased propensity to acquire additional molecular defects leading inevitably to blast crisis over a period of 3-5 years. Although a large body of work describes the molecular effects of BCR-ABL, the link between these molecular aberrations and the clinical features of CML is still not clear.
One of the most obvious characteristics of CML is the expansion of myeloid progenitors and precursors, which mature relatively normal. Increases in cell number can be the result of decreased cell death, increased production of cells, or both. The BCR-ABL protein may interfere with the ability of BCR-ABL containing cells to undergo apoptotic cell death. 6 This would not only explain the abnormal expansion of BCR- 
ABL
+ cells but also allow survival of cells with additional mutations which may then lead to blast crisis. 6 Compared with p145 ABL , p210 BCR-ABL has increased tyrosine kinase activity. 7 This causes autophosphorylation of the oncoprotein itself and phosphorylation and recruitment of a number of adaptor and signal proteins which can activate the Ras-MAPK pathway. 8 Furthermore, BCR-ABL may phosphorylate Stat-1, Stat-5 and Jak-1. Activation of both the Ras/MAPK and Jak-Stat pathways has been invoked to explain the mitogenic effect of BCR-ABL when introduced in cell lines. However, in contrast to what is seen in cell lines transfected with BCR-ABL, chronic phase Ph + CML progenitors are not growth factor independent and there is also no definitive evidence that CML progenitors are hypersensitive to cytokines. It therefore remains to be determined if direct mitogenic effects of BCR-ABL are involved in the phenotype of chronic phase CML. Some studies have invoked decreased sensitivity of CML progenitors to growth inhibitory cytokines to explain the abnormal expansion of the CML progenitor and precursor pool. 9 Although decreased apoptosis, direct mitogenic effects of BCR-ABL, or decreased response of CML progenitors to proliferation inhibitory factors may contribute to the progenitor pool expansion, they cannot explain the discrepancies in the expansion of immature and maturing erythroid and granulocytic progenitors and precursors in CML, the aberrant circulation of immature cells in the blood or the tendency for extramedullary hematopoiesis seen in CML.
In a recent review article in this Journal, Clarkson et al 10 summarized a series of very elegant studies performed by his group over the last 20-30 years that evaluate the proliferative and differentiation potential of CML progenitors. These studies start to explain discrepancies in proliferation and differentiation of the myeloid and erythroid lineage seen in CML and attempt to connect these clinical characteristics with molecular abnormalities in CML. The power of the studies from Clarkson is that evaluation was done chiefly using primary cells examined either in vivo or in vitro. The majority of studies examining molecular events emanating from the presence of the BCR-ABL oncogene have employed BCR-ABL cDNA containing cell lines, some of them of non-hematopoietic origin. 11, 12 Although these model systems allow characterization of signals involved in BCR-ABL-mediated transformation, they do not necessarily reflect the full spectrum of abnormalities seen in primary Ph + cells. For instance, in contrast to primary hematopoietic cells where p185 BCR-ABL is associated with acute lymphocytic leukemia and p210
BCR-ABL mainly with CML, the biological repercussion of transfection of cell lines with either cDNA is indistinguishable. Likewise, cell lines, but not primary chronic phase CML progenitors, are rendered cytokine independent by BCR-ABL. 6 It is not clear why the presence of BCR-ABL in cell lines and primary cells has differing biological effects. In comparison with primary cells, BCR-ABL is overexpressed in cell lines where it is transcriptionally regulated by a promoter different from the endogen-ous BCR promoter. Furthermore, in transduced or transfected cell lines, two endogenous ABL tyrosine kinases are already present. Overexpression of BCR-ABL, now coexpressed with two normal ABL genes, results in an increased 'ABL protein dose' in cell lines compared with primary Ph + cells which may account for some of the differences observed between BCR-ABL-positive cell lines and Ph + primary progenitors. Although the function of the ABL-BCR fusion gene on chromosome 9 is unknown, it is possible that the effect of the BCR-ABL fusion protein in Ph + cells is altered by the presence of this ABL-BCR gene. 13 Finally, because of its anti-apoptotic nature, overexpression of BCR-ABL in cell lines may quickly result in additional genetic abnormalities that complicate assessment of BCR-ABL-induced changes in cell lines.
In vivo as well as in vitro studies by Clarkson et al 10 showed that compared with progenitors from normal individuals, immature CML progenitors proliferate more. This explains the expansion of the immature myeloid, erythroid and megakaryocytic progenitor population. There is evidence for delayed cytoplasmic but not nuclear maturation in CML. Such discordant nuclear/cytoplasmic maturation would result in extra cell divisions of myeloid progenitors and precursors before terminal differentiation occurs leading to an expanded myeloid precursor population. In the erythroid lineage, in contrast, enucleation occurs when the cytoplasm has reached a certain stage of maturity. The more rapid cytoplasmic maturation compared with nuclear maturation in erythroid progenitors would lead to a decreased number of cell divisions and shorter survival of maturing erythroid elements. Aberrant proliferation and differentiation kinetics in the myeloid and erythroid progenitor and precursor population could thus explain both the expansion of primitive and maturing myeloid lineage cells and the expanded pool of primitive erythroid progenitors but decrease in maturing erythroid precursors. Other investigators have documented that CML BFU-E can generate significantly more rather than fewer subclones. 14 Assuming that differentiation beyond the CFU-E stage is blocked, this too would be consistent with the clinical observation that increased numbers of CFU-E can be found in CML in vivo. Differences between these studies may be related to the culture conditions used. However, the conclusion of both studies, that differences in the kinetics of proliferation and differentiation between CML and normal progenitors exist, may start to explain the characteristics increase in all progenitor populations associated with excessive numbers of mature myeloid but not erythroid cells.
It remains to be determined how BCR-ABL causes such putative abnormal proliferative and differentiation behavior of CML progenitors. In their review, Clarkson et al suggest one possible explanation. They hypothesize that constitutive, sustained phosphorylation by BCR-ABL of one or more proteins in critical signaling pathways may increase or decrease proliferation and differentiation of cells, depending on their specific stage of commitment and differentiation. In a series of experiments, they found that the constitutive phosphorylation pattern seen in primary CML cells is remarkably similar to what is seen in normal cells following stimulation with the pluripotent cytokine, stem cell factor (SCF). They characterized the most prominent phosphorylated protein common between unstimulated CML blasts and normal lineage-negative blasts following stimulation with SCF as p62 dok . 15, 16 This novel protein can bind to and inactivate Ras-GAP which may lead to activation of the Ras pathway. As p62 dok can be phosphorylated on several tyrosines it may also serve as a docking protein for other SH2-containing proteins that interface with additional signaling pathways. Future studies will have to determine if and how chronic phosphorylation of p62 dok , of other known signal or adaptor molecules that are phosphorylated in CML, 7 or novel phosphorylated substrates 10, 15, 16 contribute to the abnormal proliferation and differentiation of CML progenitors.
The studies described by Clarkson do not address the other hallmark of CML, namely the premature circulation of the massively expanded myeloid progenitor and precursor pool. 1 Consistent with the hypothesis suggested by Clarkson et al, 10 that tyrosine kinase-mediated phosphorylation of signal and adaptor molecules may underlie the abnormal proliferation and differentiation in CML, it is possible that phosphorylation of integrin-associated molecules may play a role in the abnormal adhesion of CML progenitors and precursors. A number of in vitro studies have shown that adhesion of CML progenitors to the microenvironment is defective. [17] [18] [19] Furthermore, transplantation of CML cells in xenogenic recipients favors engraftment of the Ph − benign progenitor pool, indicating that Ph + progenitors may adhere (home) poorly to the marrow microenvironment. 20, 21 Differences in the expression of adhesion receptors on CML and normal CD34 + cells have been described. 18 Furthermore, CML CD34 + adhere significantly less well to fibronectin than normal CD34 + cells 18, 19 even though the integrin expression pattern on CML and normal CD34 + cells is similar suggesting that integrins are functionally abnormal. p210 BCR-ABL phosphorylates Fak, paxillin, tensin, p130
Cas and CRKL, 7, 19 all known to play an important role in integrin-dependent focal contacts. 22 Constitutive phosphorylation of one or more of the focal contact-associated molecules may thus prevent their participation in integrinmediated signaling cascade. This hypothesis is in line with the postulate from Clarkson et al 10 that constitutive phosphorylation of signal molecules in cytokine signal pathways may cause the aberrant expansion and divergent differentiation of the myeloid and erythroid progenitor pool in CML.
Thus, although significant progress has been made in our understanding of BCR-ABL-induced alterations in intracellular signaling, we still only poorly understand the correlation between the majority of clinical symptoms of chronic phase CML and the BCR-ABL oncoprotein. This is in part due to lack of good in vivo or in vitro models of chronic phase CML. Studies, as described by Clarkson and colleagues, that examine the fate of BCR-ABL-positive primary cells both in vitro and in vivo, rather than BCR-ABL-transfected cell lines are cumbersome and labor intensive. However, these and future studies examining the effect of BCR-ABL in its 'natural setting' are dearly needed to reconcile the molecular effects of BCR-ABL and the biological characteristics of CML. Combining insights gained from studies in cell lines and in primary CML cells should lead to a better understanding of the pathophysiology of chronic phase CML.
